Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1980 1
1981 1
1984 3
1985 1
1986 1
1987 1
1988 1
1989 5
1990 2
1991 1
1993 4
1994 7
1995 1
1996 2
1997 5
1998 5
1999 3
2000 4
2001 5
2002 3
2003 8
2004 2
2005 3
2006 6
2007 6
2008 10
2009 6
2010 9
2011 9
2012 11
2013 8
2014 9
2015 6
2016 11
2017 6
2018 13
2019 6
2020 11
2021 9
2022 7
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of breast cancer.
Maughan KL, Lutterbie MA, Ham PS. Maughan KL, et al. Am Fam Physician. 2010 Jun 1;81(11):1339-46. Am Fam Physician. 2010. PMID: 20521754 Free article. Review.
This article reviews typical treatments based on stage, histology, and biomarkers. Lobular carcinoma in situ does not require treatment. Ductal carcinoma in situ can progress to invasive cancer and is treated with breast-conserving surger …
This article reviews typical treatments based on stage, histology, and biomarkers. Lobular carcinoma in situ does not r …
European guidelines for the diagnosis, treatment and follow-up of breast lesions with uncertain malignant potential (B3 lesions) developed jointly by EUSOMA, EUSOBI, ESP (BWG) and ESSO.
Rubio IT, Wyld L, Marotti L, Athanasiou A, Regitnig P, Catanuto G, Schoones JW, Zambon M, Camps J, Santini D, Dietz J, Sardanelli F, Varga Z, Smidt M, Sharma N, Shaaban AM, Gilbert F. Rubio IT, et al. Eur J Surg Oncol. 2024 Jan;50(1):107292. doi: 10.1016/j.ejso.2023.107292. Epub 2023 Nov 27. Eur J Surg Oncol. 2024. PMID: 38061151 Free article.
INTRODUCTION: Breast lesions of uncertain malignant potential (B3) include atypical ductal and lobular hyperplasias, lobular carcinoma in situ, flat epithelial atypia, papillary lesions, radial scars and fibroepithelial lesions as well as other …
INTRODUCTION: Breast lesions of uncertain malignant potential (B3) include atypical ductal and lobular hyperplasias, lobula …
Management of breast complaints and high-risk lesions.
Pleasant V. Pleasant V. Best Pract Res Clin Obstet Gynaecol. 2022 Sep;83:46-59. doi: 10.1016/j.bpobgyn.2022.03.017. Epub 2022 Apr 4. Best Pract Res Clin Obstet Gynaecol. 2022. PMID: 35570155 Review.
Practitioners should be well versed in the components of clinical breast care. Workup begins with taking a thorough medical and family history to assess risk and performing a clinical breast examination. ...High-risk breast lesions such as atypical hyp …
Practitioners should be well versed in the components of clinical breast care. Workup begins with taking a thorough medical an …
Pathologic High-risk Lesions, Diagnosis and Management.
Murray M. Murray M. Clin Obstet Gynecol. 2016 Dec;59(4):727-732. doi: 10.1097/GRF.0000000000000234. Clin Obstet Gynecol. 2016. PMID: 27681693 Free PMC article. Review.
Percutaneous imaging-guided core needle biopsy (CNB) is a less invasive and less expensive alternative to surgical biopsy for the evaluation of breast lesions. After a CNB the radiologist determine if there is concordance between the pathology, imaging, and clinical findin …
Percutaneous imaging-guided core needle biopsy (CNB) is a less invasive and less expensive alternative to surgical biopsy for the evaluation …
Diagnosis and Management of High-Risk Breast Lesions.
Thomas PS. Thomas PS. J Natl Compr Canc Netw. 2018 Nov;16(11):1391-1396. doi: 10.6004/jnccn.2018.7099. J Natl Compr Canc Netw. 2018. PMID: 30442737 Review.
Atypical hyperplasia (AH) and lobular carcinoma in situ (LCIS) are nonmalignant breast lesions that confer a 4- to 10-fold increased risk for breast cancer in women. Often, AH and LCIS are diagnosed through breast biopsy due to a mammogra …
Atypical hyperplasia (AH) and lobular carcinoma in situ (LCIS) are nonmalignant breast lesions that confer a 4- …
ACR Appropriateness Criteria Ductal Carcinoma in Situ.
Kaufman SA, Harris EE, Bailey L, Chadha M, Dutton SC, Freedman GM, Goyal S, Halyard MY, Horst KC, Novick KL, Park CC, Suh WW, Toppmeyer D, Zook J, Haffty BG. Kaufman SA, et al. Oncology (Williston Park). 2015 Jun;29(6):446-58, 460-1. Oncology (Williston Park). 2015. PMID: 26089220 Free article. Review.
Ductal carcinoma in situ (DCIS) is a breast neoplasm with potential for progression to invasive cancer. ...Several radiotherapy techniques exist beyond standard whole-breast irradiation (ie, partial-breast irradiation [PBI], hypofractionated who …
Ductal carcinoma in situ (DCIS) is a breast neoplasm with potential for progression to invasive cancer. ...Several radi …
Lobular carcinoma in situ: diagnostic criteria and molecular correlates.
Sokolova A, Lakhani SR. Sokolova A, et al. Mod Pathol. 2021 Jan;34(Suppl 1):8-14. doi: 10.1038/s41379-020-00689-3. Epub 2020 Oct 6. Mod Pathol. 2021. PMID: 33024303 Free article. Review.
Lobular neoplasia (LN) is an atypical proliferation of small, dyscohesive epithelial cells within the terminal duct lobular unit (TDLU), with or without pagetoid extension and encompasses both lobular carcinoma in situ (LCIS) and atypical lob …
Lobular neoplasia (LN) is an atypical proliferation of small, dyscohesive epithelial cells within the terminal duct lobular un …
Risk management recommendations and patient acceptance vary with high-risk breast lesions.
Beck AC, Fu SL, Liao J, Bashir A, Sugg SL, Erdahl LM, Weigel RJ, Lizarraga IM. Beck AC, et al. Am J Surg. 2022 Jan;223(1):94-100. doi: 10.1016/j.amjsurg.2021.07.020. Epub 2021 Jul 21. Am J Surg. 2022. PMID: 34325908
INTRODUCTION: Lobular carcinoma in situ (LCIS), atypical ductal and lobular hyperplasia (AH) increase breast cancer risk. ...Univariate and multivariate analysis examined factors associated with management. RESULTS: 98 % of patients were evaluat …
INTRODUCTION: Lobular carcinoma in situ (LCIS), atypical ductal and lobular hyperplasia (AH) increase breast …
Evidence-Based Pragmatic Approach to the Management of Borderline or High-Risk Breast Lesions.
Lamb LR, Bahl M. Lamb LR, et al. AJR Am J Roentgenol. 2022 Jan;218(1):186-187. doi: 10.2214/AJR.21.26340. Epub 2021 Jul 21. AJR Am J Roentgenol. 2022. PMID: 34286593 Review.
The management of borderline or high-risk breast lesions (HRLs) remains controversial. We propose a pragmatic evidence-based approach based on lesion type. For lobular carcinoma in situ with pleomorphism, papilloma with atypia, atypical ductal hyperpla …
The management of borderline or high-risk breast lesions (HRLs) remains controversial. We propose a pragmatic evidence-based approach …
Lobular neoplasia: morphology, biological potential and management in core biopsies.
O'Malley FP. O'Malley FP. Mod Pathol. 2010 May;23 Suppl 2:S14-25. doi: 10.1038/modpathol.2010.35. Mod Pathol. 2010. PMID: 20436498 Free article. Review.
Lobular neoplasia has been traditionally recognized as a marker of increased risk for subsequent breast carcinoma development; however, molecular studies suggest that it also behaves in a non-obligate precursor manner. ...Thus, the current approach of conserv …
Lobular neoplasia has been traditionally recognized as a marker of increased risk for subsequent breast carcinoma devel …
199 results